Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.607,94
0,31%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Arvinas Inc (ARVN) Arvinas Inc (ARVN) Notizie

Arvinas Inc

ARVN
32,37
0,77 (2,44%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202422:30GLOBEArvinas Appoints Randy Teel, Ph.D., as Chief Business..
11/4/202413:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
18/3/202421:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
04/3/202413:00GLOBEArvinas to Participate in Upcoming Investor Conferences
28/2/202400:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202400:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202400:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:02EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
20/2/202422:06EDGAR2Form 8-K - Current report
20/2/202422:05GLOBEArvinas Announces Chief Financial Officer Transition
20/2/202413:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
14/2/202414:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
14/2/202402:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202412:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
01/2/202422:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
16/1/202423:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
16/1/202422:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/1/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:45EDGAR2Form 8-K - Current report
08/12/202315:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
06/12/202313:01EDGAR2Form 8-K - Current report
06/12/202304:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
05/12/202319:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
28/11/202323:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
27/11/202313:11EDGAR2Form 8-K - Current report
27/11/202313:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
07/11/202323:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
07/11/202322:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:03EDGAR2Form 8-K - Current report
07/11/202313:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
02/11/202312:00GLOBEArvinas to Participate in Upcoming Investor Conferences
23/10/202314:30EDGAR2Form 8-K - Current report
22/10/202313:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
18/10/202313:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
16/10/202300:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..
16/10/202300:05GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
01/9/202313:00GLOBEArvinas to Participate in Upcoming Investor Conferences
14/8/202323:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202322:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:03EDGAR2Form 8-K - Current report
08/8/202313:00GLOBEArvinas Reports Second Quarter 2023 Financial Results and..
31/7/202322:30GLOBEArvinas and Pfizer Awarded Innovation Passport Designation..
06/7/202315:00GLOBECarrick Therapeutics Announces Clinical Trial Collaboration..
15/6/202322:30GLOBEArvinas Announces Changes to its Board of Directors
08/6/202313:00GLOBEArvinas Announces Interim Data from the ARV-766 Phase 1/2..
05/6/202313:00GLOBEArvinas to Participate in Upcoming Investor Conferences
08/5/202313:00GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
Apertura: 31,73 Min: 31,04 Max: 32,72
Chiusura: 31,60

La tua Cronologia

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network